11.78

1.29% 0.15

Design Therapeutics Inc (DSGN)

Overview News Price History Option Chain Financials Discussions Forecast

Design Therapeutics Inc stock is traded at $11.78, with a volume of 417.04K. It is up +1.29% in the last 24 hours and down -14.51% over the past month. Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Previous Close:

$11.63

Open:

$11.69

24h Volume:

417.04K

Relative Volume:

0.44

Market Cap:

$735.74M

Revenue:

Net Income/Loss:

$-69.71M

P/E Ratio:

-9.8701

EPS:

-1.1935

Net Cash Flow:

$-54.12M

1W Performance:

-6.28%

1M Performance:

-14.51%

6M Performance:

+15.72%

1Y Performance:

+191.58%

1-Day Range:

$11.37

$12.08

1-Week Range:

$11.37

$12.89

52-Week Range:

$3.76

$17.25

Design Therapeutics Inc Stock (DSGN) Company Profile

Name

Design Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

858-293-4900

Address

6005 HIDDEN VALLEY ROAD, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

DSGN's Discussions on Twitter

Compare DSGN vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DSGN Design Therapeutics Inc	11.78	735.74M	0	-69.71M	-54.12M	-1.1935
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	Jefferies	Buy
Jan-07-26	Initiated	Oppenheimer	Outperform
Dec-03-25	Initiated	Craig Hallum	Buy
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-20-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-07-24	Upgrade	Piper Sandler	Neutral → Overweight
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral
May-04-23	Upgrade	Goldman	Sell → Neutral
Jun-10-22	Initiated	Wedbush	Outperform
May-02-22	Initiated	RBC Capital Mkts	Outperform
Jan-19-22	Initiated	Goldman	Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-20-21	Initiated	Piper Sandler	Overweight
Apr-20-21	Initiated	SVB Leerink	Outperform

View All

Design Therapeutics Inc Stock (DSGN) Latest News

Jul 23, 2026

Edgewise Therapeutics, Inc. (EWTX) options chain - Yahoo Finance Singapore

Jul 23, 2026

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate - Moomoo

Jul 23, 2026

Jul 22, 2026

Fuchs Dystrophy Pipeline 2026: Therapies Under Investigation, - openPR.com

Jul 22, 2026

Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history - Yahoo Finance UK

Jul 22, 2026

Cellares and Papillon partner for PPL-001 manufacturing automation - Yahoo Finance

Jul 22, 2026

Jul 19, 2026

Design Therapeutics (DSGN) Q1 2026 earnings summary - Quartr

Jul 19, 2026

Design Therapeutics (DSGN) Leerink Global Healthcare Conference 2026 Summary - Quartr

Jul 19, 2026

Design Therapeutics (DSGN) Jefferies London Healthcare Conference 2024 Summary - Quartr

Jul 19, 2026

Jul 18, 2026

Design Therapeutics (DSGN) Proxy filing Summary - Quartr

Jul 18, 2026

Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN

Jul 18, 2026

Jul 09, 2026

DSGN Q1 2026 Earnings: EPS Surprises to the Upside Amid Ongoing Pipeline DevelopmentEPS Surprise History - dars.gov.et

Jul 09, 2026

Jul 08, 2026

Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien - Barchart.com

Jul 08, 2026

Myotonic Dystrophy Market Expected to Experience Accelerated - openPR.com

Jul 08, 2026

Design Therapeutics (DSGN) Jefferies Global Healthcare Conference 2025 Summary - Quartr

Jul 08, 2026

Jul 07, 2026

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire

Jul 07, 2026

Jul 04, 2026

If You Invested $1,000 in Design Therapeutics, Inc. (DSGN) - Stock Titan

Jul 04, 2026

Jul 03, 2026

Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView

Jul 03, 2026

Jul 02, 2026

Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView

Jul 02, 2026